StockNews.com Begins Coverage on Ekso Bionics (NASDAQ:EKSO)

Analysts at StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report issued on Thursday. The firm set a “hold” rating on the stock.

Several other brokerages also recently commented on EKSO. Lake Street Capital lowered their target price on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Ekso Bionics in a research note on Tuesday, March 4th.

Ekso Bionics Price Performance

EKSO stock opened at $0.44 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The business has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $0.74. The company has a market capitalization of $10.85 million, a P/E ratio of -0.67 and a beta of 1.43. Ekso Bionics has a 52-week low of $0.34 and a 52-week high of $1.53.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $5.09 million for the quarter, compared to the consensus estimate of $5.05 million. Research analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.